Nkarta, Inc. Insider Transaction Review

On January 15th, David Shook, an insider at Nkarta, Inc. (NASDAQ:NKTX), sold 8,638 shares of the company's stock. The shares were sold at an average price of $2.20, resulting in a total transaction value of $19,003.60. Post-transaction, Shook holds 190,955 shares valued at approximately $420,101. This sale represents a decrease of 4.33% in his ownership stake in Nkarta. The details of this stock sale were disclosed in a filing with the Securities and Exchange Commission (SEC) that is publicly available on the SEC website.

Current Stock Performance

On the recent trading day, Nkarta's stock price decreased by $0.02, bringing it to $2.47. The trading volume reached 1,770,362 shares, which is higher than its average volume of 1,352,778. The 50-day moving average for Nkarta is $2.54, while its 200-day moving average stands at $4.21. Throughout the past year, the stock has recorded a low of $2.08 and a high of $16.24. The company's market capitalization is estimated at $174.31 million, with a price-to-earnings (P/E) ratio of -1.31 and a beta of 0.85, indicating its volatility in comparison to the market.

Institutional Investor Activity

Recently, several large institutional investors have engaged in transactions involving Nkarta shares. AQR Capital Management LLC initiated a new investment in Nkarta in the second quarter, valued at $938,000. Federated Hermes Inc. significantly increased its stake in Nkarta by about 28,478.7% during the same period, now holding 135,749 shares worth $802,000 after acquiring an additional 135,274 shares. In the third quarter, Wasatch Advisors LP raised its investment in Nkarta by 31.7%, owning 1,834,680 shares now valued at $8,293,000 after adding 442,125 shares. Similarly, Geode Capital Management LLC also raised its holdings in Nkarta by 3.0%, owning 1,171,026 shares valued at $5,294,000. Cubist Systematic Strategies LLC made a new investment during the second quarter worth approximately $1,489,000. It is notable that 80.54% of Nkarta's stock is currently held by institutional investors.

Analyst Outlook

Nkarta has garnered attention from several financial analysts who have provided insights on the stock's future performance. Mizuho recently revised their price target for Nkarta from $20.00 to $16.00, while rating the stock as "outperform". On the other hand, Needham & Company LLC lowered their target from $13.00 to $11.00, maintaining a "buy" rating. Rodman & Renshaw upgraded Nkarta to a "strong-buy" rating with an initial price target of $14.00 on October 9th. HC Wainwright also reduced their price target from $22.00 to $18.00 while keeping a "buy" rating. Overall, five analysts have given Nkarta a buy rating, while two analysts have issued strong buy ratings, leading to a consensus rating of "Buy" with an average target price of $15.00.

Company Overview

Nkarta, Inc. is a biopharmaceutical company engaged in clinical-stage development of natural killer (NK) cell therapies designed for treating cancer and autoimmune diseases. The company's leading candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) therapy aimed at targeting the CD19 antigen. Currently, NKX019 is undergoing a Phase 1 clinical trial for treating relapsed/refractory non-Hodgkin lymphoma as well as lupus nephritis.

Nkarta, Stock, Trade